@article{67f769b551c14a5698731d7605db0179,
title = "The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease",
keywords = "Alzheimer's disease, Glucagon-like peptide-1, Hippocampus, Inflammation, Insulin receptor, Insulin receptor substrate-1, Insulin signaling, Liraglutide, Streptozotocin, Type 3 diabetes, Humans, Insulin Resistance, Brain/drug effects, Animals, Alzheimer Disease/drug therapy, Glucagon-Like Peptide 1/therapeutic use",
author = "Konrad Talbot and Wang, \{Hoau Yan\}",
note = "Copyright {\textcopyright} 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = feb,
doi = "10.1016/j.jalz.2013.12.007",
language = "English",
volume = "10",
pages = "S12--S25",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
number = "1 SUPPL.",
}